AU2006286568B2 - 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 - Google Patents

11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 Download PDF

Info

Publication number
AU2006286568B2
AU2006286568B2 AU2006286568A AU2006286568A AU2006286568B2 AU 2006286568 B2 AU2006286568 B2 AU 2006286568B2 AU 2006286568 A AU2006286568 A AU 2006286568A AU 2006286568 A AU2006286568 A AU 2006286568A AU 2006286568 B2 AU2006286568 B2 AU 2006286568B2
Authority
AU
Australia
Prior art keywords
methano
hexahydro
indazol
phenyl
trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006286568A
Other languages
English (en)
Other versions
AU2006286568A1 (en
Inventor
Bruce Lester Banner
Joseph Anthony Bilotta
Nader Fotouhi
Paul Gillespie
Robert Alan Goodnow Jr.
Kevin Richard Guertin
Matthew Michael Hamilton
Nancy-Ellen Haynes
Agnieszka Kowalczyk
Alexander V. Mayweg
Michael Paul Myers
Sherrie Lynn Pietranico-Cole
Nathan Robert Scott
Kshitij Chhabilbhai Thakkar
Jefferson Wright Tilley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006286568(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2006286568A1 publication Critical patent/AU2006286568A1/en
Application granted granted Critical
Publication of AU2006286568B2 publication Critical patent/AU2006286568B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2006286568A 2005-08-31 2006-08-21 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 Ceased AU2006286568B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71307405P 2005-08-31 2005-08-31
US60/713,074 2005-08-31
US81725506P 2006-06-29 2006-06-29
US60/817,255 2006-06-29
PCT/EP2006/065498 WO2007025892A1 (en) 2005-08-31 2006-08-21 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1

Publications (2)

Publication Number Publication Date
AU2006286568A1 AU2006286568A1 (en) 2007-03-08
AU2006286568B2 true AU2006286568B2 (en) 2010-12-09

Family

ID=37027691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006286568A Ceased AU2006286568B2 (en) 2005-08-31 2006-08-21 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1

Country Status (13)

Country Link
US (1) US7622492B2 (zh)
EP (1) EP1924563B1 (zh)
JP (1) JP4839377B2 (zh)
KR (1) KR100996749B1 (zh)
CN (1) CN101253155B (zh)
AR (1) AR057101A1 (zh)
AU (1) AU2006286568B2 (zh)
BR (1) BRPI0615285A2 (zh)
CA (1) CA2618857C (zh)
ES (1) ES2426011T3 (zh)
IL (1) IL189271A0 (zh)
TW (1) TW200806632A (zh)
WO (1) WO2007025892A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US9006280B2 (en) * 2008-11-20 2015-04-14 Teikoku Pharma Usa, Inc. Pyrazolone derivative formulations
CN104945315A (zh) * 2015-07-19 2015-09-30 佛山市赛维斯医药科技有限公司 一类硝基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
CN105130876A (zh) * 2015-09-08 2015-12-09 湖南博瑞新特药有限公司 新吲哚菁绿的制备工艺
CN106083633B (zh) * 2016-06-12 2021-08-24 江西农业大学 一种异莰烷基甲酰胺类化合物的合成方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3047461A (en) * 1960-06-10 1962-07-31 American Cyanamid Co Central nervous system stimulant
FR1271246A (fr) 1960-07-29 1961-09-08 Marinier Lab Phényl-1 méthyl-2 campho [3, 4-b] pyrazolone-5, son isomère o-méthylé et leur procédé de préparation
GB8410484D0 (en) 1984-04-24 1984-05-31 Scras Antiviral and antibacterial compounds
IL114670A0 (en) 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
UY27192A1 (es) 2001-03-01 2002-09-30 Smithkline Beecham Corp Inhibidores de peptido-deformilasa
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
AU2002353717B2 (en) 2001-11-22 2006-08-03 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE469136T1 (de) 2001-11-22 2010-06-15 Biovitrum Ab Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
MXPA04004837A (es) 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
GB0130705D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
AU2002360819A1 (en) * 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
JP4368683B2 (ja) 2002-02-01 2009-11-18 メルク エンド カムパニー インコーポレーテッド 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
EP1482794A1 (en) 2002-03-06 2004-12-08 Merck & Co., Inc. Method of treatment or prevention of obesity
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP2005533858A (ja) 2002-07-27 2005-11-10 アストラゼネカ アクチボラグ 化合物
US20040138258A1 (en) 2002-09-18 2004-07-15 Hanauske-Abel Hartmut M. Inhibitors of 11beta-hydroxysteroid dehydrogenase and uses therefor
BR0315047A (pt) 2002-10-03 2005-08-23 Hoffmann La Roche Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
AU2003269242A1 (en) 2002-10-11 2004-05-04 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
KR20050059294A (ko) 2002-10-24 2005-06-17 스테릭스 리미티드 11-베타-하이드록시 스테로이드 데하이드로게나제 형태 1및 형태 2의 억제제
US20060058315A1 (en) 2002-11-07 2006-03-16 Astrazeneca Ab 2-Oxo-ethanesulfonamide derivates
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
JP2006522745A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 置換１，２，４−トリアゾールの薬学的使用
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
EP1615647B1 (en) 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
EP1624876A2 (en) 2003-04-29 2006-02-15 The Miriam Hospital Selective testicular 11beta-hsd inhibitors and methods of use thereof
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
SE0301883D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301882D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301885D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use IV
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301888D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
SE0301884D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use III
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
WO2005042513A1 (en) 2003-10-23 2005-05-12 Sterix Limited Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
GB0326029D0 (en) 2003-11-07 2003-12-10 Astrazeneca Ab Chemical compounds
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
WO2005060694A2 (en) * 2003-12-18 2005-07-07 Agy Therapeutics, Inc. Treatment of neurologic disorders with inhibitors of 11beta-hsd1
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D1: ACAD. REP. POPULARE ROMINE, FILIALA IASI, STUDII CERCETARI STIINT, CHIM., 9, 83-91, 1958 (& CAS RN. 113551-62-5) *

Also Published As

Publication number Publication date
EP1924563B1 (en) 2013-07-31
AR057101A1 (es) 2007-11-14
IL189271A0 (en) 2008-08-07
CA2618857A1 (en) 2007-03-08
AU2006286568A1 (en) 2007-03-08
CA2618857C (en) 2011-03-29
US20070049632A1 (en) 2007-03-01
BRPI0615285A2 (pt) 2011-05-17
US7622492B2 (en) 2009-11-24
TW200806632A (en) 2008-02-01
EP1924563A1 (en) 2008-05-28
JP2009506092A (ja) 2009-02-12
KR20080040043A (ko) 2008-05-07
KR100996749B1 (ko) 2010-11-25
CN101253155A (zh) 2008-08-27
ES2426011T3 (es) 2013-10-18
CN101253155B (zh) 2011-11-09
JP4839377B2 (ja) 2011-12-21
WO2007025892A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
AU2008277783B2 (en) Inhibitors of 11beta-hydroxysteroid dehydrogenase
CA2602781C (en) 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase
AU2007228887B2 (en) Pyrazoles as 11-beta-HSD-1
JP4800964B2 (ja) 肥満症の治療においてグルコキナーゼ活性化剤として使用するための、ヘテロアリールインドールカルボキサミドおよびその類似体
AU2006286568B2 (en) 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
TW201107298A (en) Pyrazole derivatives, preparation and therapeutic use thereof
UA76233C2 (en) N-substituted pyrrolidine derivatives as dipeptidylpeptidase iv inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired